REMARKS

The sequence listing has been amended to reflect the source of the peptide sequences which in many of the case were derived from a phage display library.

RESTRICTION REQUIREMENT

The communication mailed May 8, 2009, indicates that the response to the previous restriction requirement was not responsive. The Communication indicates that Applicant was required to elect a specific SEQ ID NO: and a specific molecular embodiment of the integer to identify a specific sequence for search.

In the Restriction Requirement mailed January 6, 2009, the Examiner indicated Restriction to one of the following Groups:

Groups I-VI, claim(s) 1-12 and 19-23 (all in part), drawn to a polypeptide of SEQ ID NO: 1-6 and a hybrid molecule derived from SEQ ID NO:1-6.

Groups VII-XII, claims 13 and 24-25 (all in part), drawn to a method of treating or diagnosing Alzheimer's or a neurodegenerative disease using SEQ ID NO:1-6 or a hybrid molecule derived from SEQ ID NO:1-6.

Groups XIII-XVIII, claims 14-18 (all in part), drawn to a nucleic acid, vector, host cell for SEQ ID NO:1-6.

Groups XIX-XXIV, claim 26 (all in part), drawn to an anti-idiotype antibody binding to SEQ ID NO:1-6.

In Response Applicants elect the invention of Group V, claim 1-12 and 19-20 drawn to a polypeptide of SEQ ID NO:5.

The Restriction Requirement further indicated:

i. If Group I is elected, Applicant is required under PCT Rule 13.2 to elect a single disclosed molecular embodiment of the integer selected from A) 1-20, B) 1-15, C) 1-10 or D) 1-5 as recited in claims 1-2, and 5-7 for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicants elect the species of (A) wherein the integer is from 1-20. Claims 1-8, 10, 11, 12 and 19-23 are generic to the elected species.

No fee is believed to be due for the filing of the present response. The Director is authorized to charge any required fee or credit any overpayment to Deposit Account Number 50-4586, please reference the attorney docket number above.

The Examiner is invited to contact the undersigned at the below-listed telephone number, if it is believed that prosecution of this application may be assisted thereby.

Respectfully submitted,

GAVRILOVICH, DODD & LINDSEY LLP

Date: June 8, 2009 By: /Joseph R. Baker, Jr./

Joseph R. Baker, Jr. Registration No. 40,900

4660 La Jolla Village Drive, Suite 750 San Diego, California 92122 (858) 458-3607 (Main) (858) 458-9986 (Fax)